ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/IDH1-R132-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/IDH1-R132-inhibitor
7
trial(s) found.
NCT06501625
Advanced
Phase 1
Recruiting
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation (
2024-514261-19-00--S095031-210
)
IDH1 R132 inhibitor
anti-PD-L1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Cholangiocarcinoma
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06127407
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (
CHONQUER
)
IDH1 R132 inhibitor
placebo
Chondrosarcoma
NOT Dedifferentiated chondrosarcoma
NOT Mesenchymal chondrosarcoma
NOT Myxoid chondrosarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05577416
Advanced
Phase 1
Recruiting
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (
AB-218-IIT-201
)
IDH1 R132 inhibitor
Low-grade glioma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
ACTRN12624000141549
Haem
Phase 1 / Phase 2
Not yet recruiting
AMLM26/T2- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - Ivosidenib + Venetoclax (
AMLM26-T2
)
BCL2 inhibitor
IDH1 R132 inhibitor
Acute myeloid leukaemia
ACTRN12619001031156
Haem
Phase 3
Recruiting
AMLM23- placebo-controlled study to compare the event free survival of patients receiving ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. (
HOVON150-AMLSG29-18
)
IDH1 R132 inhibitor
IDH2 inhibitor
placebo
Acute myeloid leukaemia
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05876754
Advanced
Phase 3
Not recruiting
An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (
ProvIDHe
)
IDH1 R132 inhibitor
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne (COMPLETED)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (COMPLETED)
SA
5011 - Woodville South - The Queen Elizabeth Hospital (COMPLETED)
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (COMPLETED)
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Not recruiting (1)
Recruitment Country and State
VIC (5)
NSW (4)
WA (4)
QLD (3)
SA (3)
NZ (1)
TAS (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 3 (4)
Trial Type
Advanced (4)
Haem (3)
Cancer Therapy Class
IDH1
100%
IDH1 R132
100%
PD-1/PD-L1
14%
PD-L1
14%
DNA methyltransferase
14%
BCL2
14%
IDH2
14%
Facility
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3066 - Epping - Northern Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6000 - Perth - Royal Perth Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Biliary tract cancer
Cholangiocarcinoma
Gastrointestinal cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Myelodysplastic syndrome
Myeloproliferative neoplasm
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Bone cancer
Chondrosarcoma
Sarcoma
Central nervous system cancer
Glioma
Low-grade glioma
Malignant glioma
Neurological cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy